NL PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
NL PHARMA
Largest movements
- Receivables within one year -€27,080
down €27,080 (-52.8%), from €51,239 to €24,159
of which Other amounts receivable: -€24,151
- Intangible fixed assets -€9,000
down €9,000 (-57.1%), from €15,750 to €6,750
- Receivables after one year -€7,526
no longer reported in 2025 (was €7,526)
- Tax, wage and social debts -€24,754
down €24,754 (-80.3%), from €30,813 to €6,060
- Reserves -€24,418
down €24,418 (-95.1%), from €25,684 to €1,266
- Trade debts +€6,134
up €6,134 (+101.0%), from €6,076 to €12,210
- Profit (loss) carried forward -€1,457
down €1,457 (-95.8%), from -€1,521 to -€2,978
- Gross operating margin -€13,322
down €13,322 (-64.8%), from €20,551 to €7,229
- Other operating charges -€3,126
down €3,126 (-78.0%), from €4,007 to €882
- Taxes -€2,863
down €2,863 (-98.8%), from €2,897 to €34
- Financial charges -€2,122
down €2,122 (-66.9%), from €3,171 to €1,049
- Financial income -€487
down €487 (-16.1%), from €3,024 to €2,536
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €78,252 | €33,758 | -€44,495 | -56.9% |
| Fixed assets | 21/28 | €16,096 | €6,839 | -€9,258 | -57.5% |
| Intangible fixed assets | 21 | €15,750 | €6,750 | -€9,000 | -57.1% |
| Tangible fixed assets | 22/27 | €346 | €89 | -€258 | -74.4% |
| Furniture and vehicles | 24 | €346 | €89 | -€258 | -74.4% |
| Current assets | 29/58 | €62,156 | €26,919 | -€35,237 | -56.7% |
| Amounts receivable after more than one year | 29 | €7,526 | - | -€7,526 | |
| Other amounts receivable | 291 | €7,526 | - | -€7,526 | |
| Amounts receivable within one year | 40/41 | €51,239 | €24,159 | -€27,080 | -52.8% |
| Trade receivables | 40 | €4,773 | €1,844 | -€2,929 | -61.4% |
| Other amounts receivable | 41 | €46,466 | €22,315 | -€24,151 | -52.0% |
| Cash at bank and in hand | 54/58 | €29 | €107 | +€78 | +272.2% |
| Deferred charges and accrued income | 490/1 | €3,361 | €2,652 | -€709 | -21.1% |
| Total equity and liabilities | 10/49 | €78,252 | €33,758 | -€44,495 | -56.9% |
| Equity | 10/15 | €30,363 | €4,488 | -€25,875 | -85.2% |
| Contributions | 10/11 | €6,200 | €6,200 | = | 0.0% |
| Reserves | 13 | €25,684 | €1,266 | -€24,418 | -95.1% |
| Distributable reserves | 133 | €25,684 | €1,266 | -€24,418 | -95.1% |
| Profit (loss) carried forward | 14 | -€1,521 | -€2,978 | -€1,457 | -95.8% |
| Amounts payable | 17/49 | €47,889 | €29,270 | -€18,619 | -38.9% |
| Amounts payable within one year | 42/48 | €47,889 | €29,270 | -€18,619 | -38.9% |
| Trade debts | 44 | €6,076 | €12,210 | +€6,134 | +101.0% |
| Suppliers | 440/4 | €6,076 | €12,210 | +€6,134 | +101.0% |
| Advances received on contracts in progress | 46 | €11,000 | €11,000 | = | 0.0% |
| Taxes, remuneration and social security | 45 | €30,813 | €6,060 | -€24,754 | -80.3% |
| Taxes | 450/3 | €30,813 | €6,060 | -€24,754 | -80.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €9,258 | €9,258 | = | 0.0% |
| Other operating charges | 640/8 | €4,007 | €882 | -€3,126 | -78.0% |
| Gross operating margin | 9900 | €20,551 | €7,229 | -€13,322 | -64.8% |
| Operating profit (loss) | 9901 | €7,286 | -€2,911 | -€10,197 | |
| Financial income | 75/76B | €3,024 | €2,536 | -€487 | -16.1% |
| Recurring financial income | 75 | €3,024 | €2,536 | -€487 | -16.1% |
| Financial charges | 65/66B | €3,171 | €1,049 | -€2,122 | -66.9% |
| Recurring financial charges | 65 | €3,171 | €1,049 | -€2,122 | -66.9% |
| Profit (loss) for the period before taxes | 9903 | €7,139 | -€1,423 | -€8,562 | |
| Income taxes | 67/77 | €2,897 | €34 | -€2,863 | -98.8% |
| Profit (loss) for the period | 9904 | €4,242 | -€1,457 | -€5,698 | |
| Profit (loss) for the period to be appropriated | 9905 | €4,242 | -€1,457 | -€5,698 |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 6 October 2026 via checked.be.